Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia

NCT05445765 is registered in ClinicalTrials.gov with iCell Gene Therapeutics as lead sponsor.

NCT NCT05445765
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05445765 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-CD33 CAR-T Cells for the Treatment of Relapsed/Refractory CD33+ Acute Myeloid Leukemia
Lead sponsor
iCell Gene Therapeutics
Phase
Phase 1
Overall status
Unknown status
Start date
July 1, 2022
Completion date
June 30, 2024
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk hematologic malignancies, relapsed and/or refractory acute myeloid leukemia